Skip to main navigation menu Skip to main content Skip to site footer

Viewpoint

Vol. 143 No. 4344 (2013)

Antihypertensive treatment – navigating between cost, compliance and complications

  • David Conen
DOI
https://doi.org/10.4414/smw.2013.13857
Cite this as:
Swiss Med Wkly. 2013;143:w13857
Published
20.10.2013

References

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
  2. Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335:432.
  3. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. Circulation. 2009;119:2146–52.
  4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.
  5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.
  6. Schäfer H, Schenuert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. Swiss Med Wkly. 2013;143:w13854 http://www.smw.ch/content/smw-2013-13854/.
  7. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–7 e1.

Most read articles by the same author(s)